Core Insights - OXB has been awarded the 'Most Innovative CDMO (Cell & Gene Therapy)' at the CDMO Leadership Awards in New York City, highlighting its leadership and innovation in the CDMO industry [1][2] - This recognition follows OXB's previous accolades, including a win in the 'Cell & Gene Therapy – Global' category in 2025 and being named a Champion in the 'Cell & Gene Therapy' category at the CDMO Leadership Awards Europe [2] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver life-changing therapies worldwide [4][5] - The company has 30 years of experience in viral vectors, which are essential for most cell and gene therapies, and collaborates with leading pharmaceutical and biotechnology companies [5] - OXB's capabilities span from early-stage development to commercialization, supported by robust quality-assurance systems and regulatory expertise [5] Technological Capabilities - OXB offers a wide range of technologies for viral vector manufacturing, including the 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6] - The company employs advanced processes such as suspension and perfusion using process enhancers, along with stable producer and packaging cell lines [6] Facilities and Presence - OXB is headquartered in Oxford, UK, with development and manufacturing facilities located in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford MA and Durham NC, US [7]

Core Insights - OXB expects to report revenues for FY 2025 at the upper end of guidance, with a significant growth trajectory and a pivot towards EBITDA profitability [2][3][8] - The company reiterates its financial guidance for 2026, maintaining expectations for continued revenue growth and improved EBITDA margins [9][20] Financial Performance - For FY 2025, OXB anticipates revenues between £166-169 million, reflecting a nearly 30% increase from FY 2024 revenues of £128.8 million and almost 90% growth since FY 2023 [3][8] - The expected Operating EBITDA profitability for FY 2025 is mid-to-high single-digit million pounds, including a non-recurring gain from the acquisition of a manufacturing facility [4][19] - The contracted value of client orders reached £224 million for FY 2025, a 20% increase from £186 million in FY 2024, indicating strong demand for OXB's services [6][8] Future Outlook - FY 2026 revenues are projected to be between £220-240 million, with anticipated year-on-year growth of 25-30% in 2027 and 2028, outpacing the broader market [9][20] - Operating EBITDA margin is expected to exceed 10% in FY 2026 and reach at least 20% for FY 2027, with long-term potential approaching 30% as capacity expands [9][20][21] Operational Efficiency - The company has demonstrated improved operational efficiency across its global network, contributing to sustained revenue growth and profitability [3][4] - A strong balance sheet is maintained, with a gross cash position of £96.9 million and a net cash position of £55.4 million, bolstered by a £60 million equity raise and a new loan facility [5][6]

Core Insights - OXB, a leading CDMO in cell and gene therapy, will participate in several upcoming investor conferences and events, showcasing its commitment to engaging with investors [2][3]. Conferences and Events - OXB will attend the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London [3]. - A virtual event, the Jefferies C-Suite "Back to School" Fireside Chat, is scheduled for November 4, 2025, with live webcasts available on OXB's website [3][4]. - Additional financial events can be found on the company's investor calendar [4]. Company Overview - OXB has 30 years of experience in viral vectors, essential for most cell and gene therapies, and collaborates with innovative pharmaceutical and biotechnology companies [7]. - The company offers a range of technologies for viral vector manufacturing, including the TetraVecta™ system for lentiviral vector production and advanced AAV production methods [9]. - OXB is a FTSE250 and FTSE4Good constituent, with facilities in the UK, France, and the US, emphasizing its global presence and capabilities [9].

Core Viewpoint - OXB has shown strong commercial momentum and operational progress in 2025, continuing to provide viral vector manufacturing services to a diverse client base, and remains on track to meet its financial outlook for the year ended December 31, 2024 [2][3]. Group 1: Company Performance - OXB has delivered strong operational performance in the first half of 2025, reflecting disciplined execution across global sites and sustained commercial momentum [3]. - The company reiterates its financial guidance and remains focused on supporting clients at all development stages, expressing confidence in its near and medium-term targets [3]. Group 2: Company Background - OXB is a pioneer in cell and gene therapy with 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [5]. - The company provides expertise in various viral vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus, supporting capabilities from early-stage development to commercialization [5]. Group 3: Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (TetraVecta™) and a dual-plasmid system for AAV production [6]. - The company utilizes advanced processes such as suspension and perfusion with process enhancers, along with stable producer and packaging cell lines [6]. Group 4: Corporate Information - OXB is headquartered in Oxford, UK, with development and manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US [7].

Core Insights - OXB has launched the Innovation and Technology Excellence Board (ITEB) to enhance its capabilities in cell and gene therapy and maintain its leadership position in the market [1][2][3] Company Overview - OXB is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, with a mission to enable clients to deliver transformative therapies to patients [15][16] - The company has 30 years of experience in viral vectors, collaborating with innovative pharmaceutical and biotechnology companies [16] Strategic Initiatives - The ITEB will provide strategic insights to identify opportunities for scientific enhancement and innovation, ensuring OXB remains at the forefront of technology development [2][3] - The board aims to improve treatment development, manufacturing, and delivery processes, focusing on practical advances for clients and better patient outcomes [3] Leadership and Expertise - The ITEB is chaired by Prof. Dame Kay Davies, a respected figure in human genetics, with founding members including leading experts in molecular biology, gene therapy, and biopharmaceuticals [3][4][5][6][7] - Dr. Frank Mathias, CEO of OXB, emphasizes the importance of the ITEB in adapting to scientific and technological changes to better serve clients [3][10] Technological Capabilities - OXB offers unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system and advanced AAV production methods [17] - The company supports its capabilities with robust quality-assurance systems and regulatory expertise, facilitating a range of services from early-stage development to commercialization [16]